Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose involved-site radiotherapy plus anti-CD20 maintenance in PR follicular lymphoma (Phase II)
ChiCTR2500109112Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and obinutuzumab in follicular lymphoma (FL), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 12-month complete response rate (CR12) by IRC on PET-CT. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
rituximabobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2500109112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109112.